Cardea Bio is developing biology-based transistors for linking biology directly up to computers. These transistors leverage graphene and are designed to replace optical static observations with interactive live-streams of multi-omics signal analysis, representing a new life science observation paradigm according to the company, where multi-omics data-streams will be the new norm instead of most of the current standard technologies that are single-omics frozen-in-time datasets.
The company’s approach of linking biology directly to compute power and converting real-time biological signals to digital information allows for immediate biological insight that can power a new generation of applications across human health, agriculture, food and water safety, diagnostics, biosafety, and the environment.
Innovation: Biology-based transistors that are used as Digital Biosensors, designed to replace optical static observations with interactive live-streams of multi-omics signal analysis.
Potential application areas: Human health, agriculture, food and water safety, diagnostics, biosafety, and the environment.
The company recently launched the CRISPR-Chip™, that is built with its proprietary Cardean Transistors. The chipset uses CRISPR as the transistor gate, and thereby harvests CRISPR’s powerful natural ability to search through genomes for genetic sequences of interest. This is all accomplished without the need of PCR/DNA amplification, enabling the user to observe the CRISPR search activity and results live on a computer screen.
The CRISPR-Chip is one of multiple chipsets Cardea offers its partners via the Cardea Innovation Partnership Program, which is the core of the Company’s business model. The company expects a number of “Powered by Cardea” products to launch in 2020 and 2021.
Subscribe for alerts on new companies featured on Startups.Bio
- Archon BiosciencesArchon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to… Read more: Archon Biosciences
- Cytospire TherapeuticsFounded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune… Read more: Cytospire Therapeutics
- This Week in Biotech Venture CapitalThe biotech sector continues to see a strong flow of new venture… Read more: This Week in Biotech Venture Capital
- THRONCATTHRONCAT is a new startup that aims to transform the field of… Read more: THRONCAT